220 related articles for article (PubMed ID: 1971431)
1. Dynorphin prolongs the action potential of mouse sensory ganglion neurons by decreasing a potassium conductance whereas another specific kappa opioid does so by increasing a calcium conductance.
Shen KF; Crain SM
Neuropharmacology; 1990 Apr; 29(4):343-9. PubMed ID: 1971431
[TBL] [Abstract][Full Text] [Related]
2. Dynorphin prolongs the action potential duration of mouse sensory ganglion neurons by decreasing a K+ conductance whereas the specific kappa opioid, U-50,488H does so by increasing a Ca2+ conductance.
Shen KF; Crain SM
Prog Clin Biol Res; 1990; 328():343-6. PubMed ID: 1968268
[No Abstract] [Full Text] [Related]
3. Dual opioid modulation of the action potential duration of mouse dorsal root ganglion neurons in culture.
Shen KF; Crain SM
Brain Res; 1989 Jul; 491(2):227-42. PubMed ID: 2548663
[TBL] [Abstract][Full Text] [Related]
4. Opioids excite rather than inhibit sensory neurons after chronic opioid exposure of spinal cord-ganglion cultures.
Crain SM; Shen KF; Chalazonitis A
Brain Res; 1988 Jul; 455(1):99-109. PubMed ID: 2458169
[TBL] [Abstract][Full Text] [Related]
5. Kappa agonists inhibit gastric emptying but not acid secretion in rhesus monkeys.
Touzeau PL; Shea-Donohue T
J Pharmacol Exp Ther; 1990 Jun; 253(3):1010-6. PubMed ID: 1972746
[TBL] [Abstract][Full Text] [Related]
6. After GM1 ganglioside treatment of sensory neurons naloxone paradoxically prolongs the action potential but still antagonizes opioid inhibition.
Crain SM; Shen KF
J Pharmacol Exp Ther; 1992 Jan; 260(1):182-6. PubMed ID: 1731037
[TBL] [Abstract][Full Text] [Related]
7. Actions of mu, delta and kappa opioid agonists and antagonists on mouse primary afferent neurons in culture.
Werz MA; Grega DS; MacDonald RL
J Pharmacol Exp Ther; 1987 Oct; 243(1):258-63. PubMed ID: 2822900
[TBL] [Abstract][Full Text] [Related]
8. Voltage-dependent effects of opioid peptides on hippocampal CA3 pyramidal neurons in vitro.
Moore SD; Madamba SG; Schweitzer P; Siggins GR
J Neurosci; 1994 Feb; 14(2):809-20. PubMed ID: 7905518
[TBL] [Abstract][Full Text] [Related]
9. Spinal involvement of both dynorphin A and Met-enkephalin in the antinociception induced by intracerebroventricularly administered bremazocine but not morphine in the mouse.
Tseng LF; Collins KA
J Pharmacol Exp Ther; 1993 Sep; 266(3):1430-8. PubMed ID: 8103794
[TBL] [Abstract][Full Text] [Related]
10. Dual excitatory and inhibitory effects of opioids on intracellular calcium in neuroblastoma x glioma hybrid NG108-15 cells.
Jin W; Lee NM; Loh HH; Thayer SA
Mol Pharmacol; 1992 Dec; 42(6):1083-9. PubMed ID: 1336113
[TBL] [Abstract][Full Text] [Related]
11. Roles of mu, delta and kappa opioid receptors in spinal and supraspinal mediation of gastrointestinal transit effects and hot-plate analgesia in the mouse.
Porreca F; Mosberg HI; Hurst R; Hruby VJ; Burks TF
J Pharmacol Exp Ther; 1984 Aug; 230(2):341-8. PubMed ID: 6086883
[TBL] [Abstract][Full Text] [Related]
12. kappa- and mu-Opioid inhibition of N-type calcium currents is attenuated by 4beta-phorbol 12-myristate 13-acetate and protein kinase C in rat dorsal root ganglion neurons.
King AP; Hall KE; Macdonald RL
J Pharmacol Exp Ther; 1999 Apr; 289(1):312-20. PubMed ID: 10087019
[TBL] [Abstract][Full Text] [Related]
13. Dynorphin and neoendorphin peptides decrease dorsal root ganglion neuron calcium-dependent action potential duration.
Werz MA; Macdonald RL
J Pharmacol Exp Ther; 1985 Jul; 234(1):49-56. PubMed ID: 2409273
[TBL] [Abstract][Full Text] [Related]
14. Dynorphin A decreases voltage-dependent calcium conductance of mouse dorsal root ganglion neurones.
Macdonald RL; Werz MA
J Physiol; 1986 Aug; 377():237-49. PubMed ID: 2432242
[TBL] [Abstract][Full Text] [Related]
15. Dynorphin reduces voltage-dependent calcium conductance of mouse dorsal root ganglion neurons.
Werz MA; Macdonald RL
Neuropeptides; 1984 Dec; 5(1-3):253-6. PubMed ID: 6152324
[TBL] [Abstract][Full Text] [Related]
16. Activation of the cloned human kappa opioid receptor by agonists enhances [35S]GTPgammaS binding to membranes: determination of potencies and efficacies of ligands.
Zhu J; Luo LY; Li JG; Chen C; Liu-Chen LY
J Pharmacol Exp Ther; 1997 Aug; 282(2):676-84. PubMed ID: 9262330
[TBL] [Abstract][Full Text] [Related]
17. Serotonergic involvement in the antinociceptive action of and the development of tolerance to the kappa-opioid receptor agonist, U-50, 488H.
Ho BY; Takemori AE
J Pharmacol Exp Ther; 1989 Aug; 250(2):508-14. PubMed ID: 2547935
[TBL] [Abstract][Full Text] [Related]
18. Dynorphin selectively augments the M-current in hippocampal CA1 neurons by an opiate receptor mechanism.
Madamba SG; Schweitzer P; Siggins GR
J Neurophysiol; 1999 Oct; 82(4):1768-75. PubMed ID: 10515966
[TBL] [Abstract][Full Text] [Related]
19. Activation of kappa opioid receptors by U50488H and morphine enhances the release of substance P from rat trigeminal nucleus slices.
Suarez-Roca H; Maixner W
J Pharmacol Exp Ther; 1993 Feb; 264(2):648-53. PubMed ID: 7679733
[TBL] [Abstract][Full Text] [Related]
20. Maturation of opioid sensitivity of fetal mouse dorsal root ganglion neuron perikarya in organotypic cultures: regulation by spinal cord.
Chalazonitis A; Crain SM
Neuroscience; 1986 Apr; 17(4):1181-98. PubMed ID: 3520378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
